Finland-based Desentum, a pharmaceutical startup specialised in developing an allergy vaccine that uses modified hypoallergenic proteins to switch the immune system’s response to allergens, raised Euro 8 million on 21st January 2022.
Investors: The investment round was led by Springvest Oyj, a Finnish investment company.
Purpose of funding: The startup intends to invest in clinical development using the funding. In addition, researchers will continue to pursue research and development for hypoallergenic products, including pollen and peanuts. The startup is seeking partnerships to conduct clinical trials and expand its market reach.
About Desentum
Founded in 2011 by Pekka Mattila, Desentum is located in Espoo, Finland. Desentum is a pharmaceutical startup that specialises in developing an allergy vaccine that uses modified hypoallergenic proteins to switch the immune system’s response to allergens. As part of the allergy vaccine, modified allergen proteins are used to improve allergen immunotherapy efficiency while also shortening treatment time. First-in-human clinical testing has been completed on DM-101, a birch pollen hypoallergenic product candidate. DM-101 was an effective and safe treatment in the study. The startup is developing the product. Moreover, the startup’s previous dosing regimens and immunological marker results indicated that a protective response was associated with a positive change in those markers.
In Europe, allergies are among the most prevalent chronic conditions. However, Immunotherapy is the only treatment known to affect allergies in their mechanism. A few years of Immunotherapy usually follow the injections or sublingual tablets or drops. The startup is one of the pharmaceutical companies working on boosting treatment speed. Therefore, increasing vaccine accuracy, safety, and convenience.
What the founder has to say
“Allergy treatment is still waiting for a breakthrough that would free hundreds of millions of people from the yearly misery during pollen season or the fear of common food items. Desentum is working towards this kind of breakthrough. The safety of the patients is the basis of all drug development, and the goal is naturally a product that is clinically proven safe and efficacious. Desentum’s team is very motivated and experienced, and we have connections to international experts as well as top-class research groups and service providers. We are determined to continue towards both our scientific and business goals and this funding provides us with the resources to focus on achieving the goals,” said Pekka Mattila, founder and CEO at Desentum.
For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.
We try our 2022 best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
Next Article
